Saudi Arabia’s SFDA has approved Leqembi (lecanemab), the Kingdom’s first Alzheimer’s treatment. This innovative drug slows disease progression by targeting beta-amyloid plaques, protein clumps that disrupt brain cell communication. Approved for patients with mild symptoms and specific genetic profiles, Leqembi requires careful monitoring to manage side effects, marking a major step forward in Alzheimer’s care through advanced biotechnology.